Nkarta is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies to treat cancer. Nkarta seeks to improve upon the efficacy of cell therapy, making it more potent, better tolerated and more rapidly available to a broad population of patients with a variety of hematologic and solid tumor malignancies.
NKX019 Clinical Update Presentation - December 2022
NKX101 and NKX019 Initial Clinical Data Presentation – April 2022
Data Provided by Refinitiv. Minimum 15 minutes delayed.
Mar 16, 2023
Feb 09, 2023
Jan 09, 2023
Mar 8, 2023 at 2:10 PM EST
Feb 28, 2023 at 2:30 PM EST
Feb 14, 2023 at 3:40 PM EST